These discoveries not only reveal a novel mechanism underlying the action of HDAC inhibitors in HCC but also suggest a promising combination strategy employing anti-PD-1 antibodies for clinical translation. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.